LLY
Snapshot
mcap $1.3T · fwd P/E 28.7 · P/S 14.6 · rev +39% y/y · margin 32% · short 0.8% of float · beta 0.5 · 95% of 52w range
Active theses holding LLY
Recent news
Eli Lilly stock up on 23% weight loss drug combo trial results
Eli Lilly's experimental combination therapy, EloraTZP (eloralintide plus tirzepatide, sold as Zepbound), achieved up to 23.3% average weight loss (54.1 lbs) over 48 weeks in a Phase 2b trial, significantly outperforming
Sep 30, 2026
Eli Lilly stock up 3.1% on FDA approval of once-weekly insulin Onswik
Eli Lilly's once-weekly insulin Onswik (insulin efsitora alfa-gobe) has received FDA approval for adults with type 2 diabetes, to be used alongside diet and exercise, setting up a direct market battle with Novo Nordisk's
Sep 24, 2026
Merck Stock Rose 89% on Pipeline Promise, Enlicitide Readout
Merck stock surged 89% from mid-September 2025, outperforming the S&P 500 and rivals, driven by pipeline progress despite weak sales. In February 2025, management touted 20 potential blockbuster growth drivers worth over
Sep 22, 2026
Eli Lilly Partners with QurCan on Genetic Medicines for Nervous System
Eli Lilly has entered an exclusive research collaboration with QurCan Therapeutics to develop genetic medicines for nervous system diseases, leveraging QurCan's polymer lipid nanoparticle delivery platform for central an
Sep 18, 2026
Eli Lilly Stock 30% Undervalued Despite FDA Approval, DCF Shows
Eli Lilly stock appears roughly 30% undervalued per a Discounted Cash Flow (DCF) model, which estimates an intrinsic value of about $1,688 per share against a recent lower share price. The DCF analysis projects growing f
Aug 31, 2026
OmniAb Partners with Eli Lilly for Ion Channel Therapeutics
On August 17, OmniAb announced a global collaboration with Eli Lilly to discover and develop novel ion channel therapeutics. The deal grants Lilly exclusive global commercialization rights in exchange for an upfront paym
Aug 28, 2026
Eli Lilly adds Alzheimer's deal, obesity cost data support Zepbound
Eli Lilly has entered a research collaboration with BioArctic to use its BrainTransporter technology for a potential Alzheimer's treatment, expanding Lilly's neurodegenerative disease work beyond its diabetes and obesity
Aug 26, 2026
LLY vs ABBV: Which Drugmaker Has Stronger Growth Prospects?
Eli Lilly and AbbVie are leading U.S. drugmakers with strong portfolios and pipelines, but Lilly's growth prospects are currently driven by its cardiometabolic franchise. Lilly's Mounjaro and Zepbound generated $27.6 bil
Aug 25, 2026
Think you know where LLY goes next? Post the thesis and the AI scores it against live news.
Sign up free